Literature DB >> 22434860

Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.

Matthew P Fox1, Mhairi Maskew, A Patrick MacPhail, Lawrence Long, Alana T Brennan, Daniel Westreich, William B MacLeod, Pappie Majuba, Ian M Sanne.   

Abstract

The Themba Lethu Clinical Cohort was established in 2004 to allow large patient-level analyses from a single HIV treatment site to evaluate National Treatment Guidelines, answer questions of national and international policy relevance and to combine an economic and epidemiologic focus on HIV research. The current objectives of the Themba Lethu Clinical Cohort analyses are to: (i) provide cohort-level information on the outcomes of HIV treatment; (ii) evaluate aspects of HIV care and treatment that have policy relevance; (iii) evaluate the cost and cost-effectiveness of different approaches to HIV care and treatment; and (iv) provide a platform for studies on improving HIV care and treatment. Since 2004, Themba Lethu Clinic has enrolled approximately 30,000 HIV-positive patients into its HIV care and treatment programme, over 21,000 of whom have received anti-retroviral therapy since being enrolled. Patients on treatment are typically seen at least every 3 months with laboratory monitoring every 6 months to 1 year. The data collected include demographics, clinical visit data, laboratory data, medication history and clinical diagnoses. Requests for collaborations on analyses can be submitted to our data centre.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434860      PMCID: PMC3619949          DOI: 10.1093/ije/dys029

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  41 in total

1.  Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa.

Authors:  Bruce A Larson; Alana Brennan; Lynne McNamara; Lawrence Long; Sydney Rosen; Ian Sanne; Matthew P Fox
Journal:  Bull World Health Organ       Date:  2010-04-16       Impact factor: 9.408

2.  Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment.

Authors:  Alana T Brennan; Lawrence Long; Mhairi Maskew; Ian Sanne; Imogen Jaffray; Patrick MacPhail; Matthew P Fox
Journal:  AIDS       Date:  2011-10-23       Impact factor: 4.177

3.  Kaposi's Sarcoma Associated-Herpes Virus (KSHV) Seroprevalence in Pregnant Women in South Africa.

Authors:  Babatyi I Malope-Kgokong; Patrick Macphail; Georgina Mbisa; Edith Ratshikhopha; Mhairi Maskew; Lara Stein; Freddy Sitas; Denise Whitby
Journal:  Infect Agent Cancer       Date:  2010-08-31       Impact factor: 2.965

4.  Effect of pulmonary tuberculosis on mortality in patients receiving HAART.

Authors:  Daniel Westreich; Patrick MacPhail; Annelies Van Rie; Babatyi Malope-Kgokong; Prudence Ive; Dennis Rubel; Ronan Boulmé; Joseph Eron; Ian Sanne
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

5.  Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.

Authors:  Sydney Rosen; Lawrence Long; Matthew Fox; Ian Sanne
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

6.  The effect of tuberculosis on mortality in HIV positive people: a meta-analysis.

Authors:  Masja Straetemans; Ana L Bierrenbach; Nico Nagelkerke; Philippe Glaziou; Marieke J van der Werf
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

7.  The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.

Authors:  Sydney Rosen; Lawrence Long; Ian Sanne; Wendy S Stevens; Matthew P Fox
Journal:  J Int AIDS Soc       Date:  2011-05-15       Impact factor: 5.396

8.  Pregnancy and virologic response to antiretroviral therapy in South Africa.

Authors:  Daniel Westreich; Stephen R Cole; Shashi Nagar; Mhairi Maskew; Charles van der Horst; Ian Sanne
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240

9.  Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa.

Authors:  Mhairi Maskew; A Patrick Macphail; Denise Whitby; Matthias Egger; Carole L Wallis; Matthew P Fox
Journal:  Infect Agent Cancer       Date:  2011-11-17       Impact factor: 2.965

Review 10.  Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.

Authors:  Sydney Rosen; Matthew P Fox; Christopher J Gill
Journal:  PLoS Med       Date:  2007-10-16       Impact factor: 11.069

View more
  63 in total

1.  Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.

Authors:  Kate Shearer; Mhairi Maskew; Toyin Ajayi; Rebecca Berhanu; Pappie Majuba; Ian Sanne; Matthew P Fox
Journal:  Int J Infect Dis       Date:  2014-03-25       Impact factor: 3.623

2.  Cervical cancer risk and impact of Pap-based screening in HIV-positive women on antiretroviral therapy in Johannesburg, South Africa.

Authors:  Eliane Rohner; Mazvita Sengayi; Bridgette Goeieman; Pamela Michelow; Cynthia Firnhaber; Mhairi Maskew; Julia Bohlius
Journal:  Int J Cancer       Date:  2017-05-19       Impact factor: 7.396

3.  Treatment outcomes of HIV-infected adolescents attending public-sector HIV clinics across Gauteng and Mpumalanga, South Africa.

Authors:  Denise Evans; Colin Menezes; Kay Mahomed; Philippa Macdonald; Sanlie Untiedt; Leon Levin; Imogen Jaffray; Nainisha Bhana; Cindy Firnhaber; Mhairi Maskew
Journal:  AIDS Res Hum Retroviruses       Date:  2013-02-25       Impact factor: 2.205

4.  Implementation and Operational Research: Risk Charts to Guide Targeted HIV-1 Viral Load Monitoring of ART: Development and Validation in Patients From Resource-Limited Settings.

Authors:  Manuel Koller; Geoffrey Fatti; Benjamin H Chi; Olivia Keiser; Christopher J Hoffmann; Robin Wood; Hans Prozesky; Kathryn Stinson; Janet Giddy; Portia Mutevedzi; Matthew P Fox; Matthew Law; Andrew Boulle; Matthias Egger
Journal:  J Acquir Immune Defic Syndr       Date:  2015-11-01       Impact factor: 3.731

5.  A hospital-based tuberculosis focal point to improve tuberculosis care provision in a very high burden setting.

Authors:  E Jong; I M Sanne; A van Rie; C N Menezes
Journal:  Public Health Action       Date:  2013-03-21

6.  Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa.

Authors:  Alana T Brennan; Kaitlyn M Berry; Sydney Rosen; Andrew Stokes; Nigel J Crowther; Jaya George; Frederick Raal; Naseem Cassim; Ian Sanne; Lawrence Long; Matthew P Fox
Journal:  AIDS       Date:  2019-11-01       Impact factor: 4.177

7.  Social and behavioral factors associated with failing second-line ART - results from a cohort study at the Themba Lethu Clinic, Johannesburg, South Africa.

Authors:  Denise Evans; Sara Dahlberg; Rebecca Berhanu; Tembeka Sineke; Caroline Govathson; Ingrid Jonker; Elisabet Lönnermark; Matthew P Fox
Journal:  AIDS Care       Date:  2018-02-21

8.  Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.

Authors:  Alana T Brennan; Kate Shearer; Mhairi Maskew; Lawrence Long; Ian Sanne; Matthew P Fox
Journal:  Trop Med Int Health       Date:  2014-03-03       Impact factor: 2.622

9.  Kaposi sarcoma-associated herpes virus and response to antiretroviral therapy: a prospective study of HIV-infected adults.

Authors:  Mhairi Maskew; A Patrick MacPhail; Denise Whitby; Matthias Egger; Matthew P Fox
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

10.  Prevalence of common vitamin D receptor gene polymorphisms in HIV-infected and uninfected South Africans.

Authors:  Lynne McNamara; Simbarashe Takuva; Tobias Chirwa; Patrick MacPhail
Journal:  Int J Mol Epidemiol Genet       Date:  2016-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.